Healthcare
Hospitals
from 8,826 today
We are building in 18%/23% revenue/EBITDA CAGR over FY26–28E led by factors such as strategic expansion plans and turnaround in ex-hospital business. Maintain 'BUY' with a TP of INR10,220.
Consolidated revenue/EBITDA/PAT grew 21%/28%/34% YoY to INR 70.4/10.9/5.8bn, with EBITDA margin improving 90bps YoY to 15.5%.
Apollo Hospitals reported a strong Q1FY27 beat driven by the addition of five new hospitals and improved operating performance in Healthco. We raise our FY27/28E EPS by ~2-4% and maintain HOLD with a higher target price of INR 8,500.
Apollo Hospitals Enterprise reported a strong Q1FY27 with consolidated EBITDA improving 28% YoY, beating estimates by 4%, driven by a strong show in the hospital segment and healthy occupancy growth. Overall, we estimate 25% EBITDA CAGR over FY26-28E and maintain our 'BUY' rating with a revised target price of INR 10,000/share.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
